Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > BUSINESS
BUSINESS
- Teva Takeda to License 10 APIs/20 Products from Sawai as It Plans to Shutter In-House Plants
August 21, 2019
- Big 3 Generic Players Braced for Average 9.2% Price Cut in October Re-Pricing
August 20, 2019
- Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey
August 20, 2019
- Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push
August 19, 2019
- Pharmacist Average Monthly Salary Down 9,636 Yen: Survey
August 19, 2019
- Osaka Univ. Spinout StemRIM Makes Tepid TSE Debut
August 16, 2019
- Towa Starts Joint Research with National CV Center on Disease Prevention, Healthy Life Expectancy Extension
August 16, 2019
- AstraZeneca Japan Adjusts Company Rules for Same-Sex, Common-Law Couples
August 16, 2019
- Otsuka Rings Up Double-Digit Growth in H1 Pharma Sales
August 9, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Ono Seeks Label Expansion for Onoact Sepsis-Associated Tachyarrhythmia
August 9, 2019
- Mitsubishi Tanabe’s Schizophrenia Drug Cariprazine Approved in 2 Asian Nations
August 9, 2019
- Mitsubishi Tanabe Submits PI Study Protocol for Spinal Cord Injury Treatment MT-3921 in US
August 9, 2019
- Sumitomo Dainippon Going Full Tilt for Napabucasin Colorectal Cancer Trial after Pancreatic Flop
August 8, 2019
- Mitsubishi Tanabe’s ALS Drug Gains Chinese Approval
August 8, 2019
- Meiji Launches 2 Santen Eye Drugs in Indonesia
August 8, 2019
- Life Science Institute’s Muse Cell Product Processing Facility Bags Manufacturing License
August 8, 2019
- Japan Ethical Drug Sales Up 0.2% in June: Crecon
August 8, 2019
- Novartis’ Entresto Filed in Japan for Chronic Heart Failure
August 7, 2019
- Keytruda Top-Selling Drug in Japan in April-June: IQVIA
August 7, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…